Endometrial carcinomas can be classified into two clinico-pathological grou
ps: estrogen-related (Type I) and estrogen-unrelated (Type II) tumors. Type
I tumors are endometrioid adenocarcinomas and generally arise from their p
recursor, endometrial hyperplasia. The expression of hormone-related protei
ns such as sex steroid receptors, pS2 protein, LH/hCG receptor, heat shock
protein 90kDa (HSP90), and bcl-2 protein is a characteristic of endometrial
hyperplasias and well differentiated endometrioid adenocarcinomas, and may
be implicated in the early development of the tumor. Transforming growth f
actor-alpha (TGF-alpha) and insulin-like growth factor-1 (IGF-1) are presum
ed to support the growth of endometrioid carcinoma under the influence of e
strogens, In tumors undergoing the hyperplasia-carcinoma sequence, mutation
of the K-ms oncogene or PTEN/MMAC1 tumor suppressor gene is an early event
, followed only later by over-expression of p53 protein, cyclin D1, c-erbB-
2 protein, and epidermal growth factor receptor (EGFR),
Type II tumors are nonendometrioid adenocarcinomas, such as serous adenocar
cinoma and clear-cell adenocarcinoma, both of which show biologically aggre
ssive behavior. Most of these carcinomas do not express sex steroid recepto
rs, and they may develop in a hormone-independent manner. Mutation and/or o
ver-expression of p53 protein is significantly more common in serous and cl
ear-cell tumors than in endometrioid carcinomas. The putative precursor of
serous carcinoma, endometrial intraepithelial carcinoma (EIC), also shows p
53 over-expression. Thus, p53 overexpression is an early event in the carci
nogenesis of serous carcinomas. DNA aneuploidy and c-myc amplification are
more frequent, but bcl-2 expression and microsatellite instability are less
prevalent in serous carcinomas.
Inherited endometrial carcinomas have recently been classed as "Type III" t
umors. Most of these tumors exhibit microsatellite instability and a good p
rognosis. Finally, endometrial carcinomas induced by prolonged tamoxifen th
erapy in breast cancer patients are worthy of mention.